ORKA
NASDAQ · Biotechnology
Oruka Therapeutics Inc
$38.91
+0.09 (+0.23%)
Financial Highlights (FY 2025)
Revenue
372.50M
Net Income
-104,674,461
Gross Margin
52.2%
Profit Margin
-28.1%
Rev Growth
-6.8%
D/E Ratio
0.83
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.2% | 52.2% | 52.2% |
| Operating Margin | -26.6% | -26.1% | -27.1% |
| Profit Margin | -28.1% | -23.9% | -26.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Gross Profit | 194.41M | 183.63M | 157.61M |
| Operating Income | -99,218,742 | -92,005,651 | -81,838,587 |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Gross Margin | 52.2% | 52.2% | 52.2% |
| Operating Margin | -26.6% | -26.1% | -27.1% |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| Rev Growth | -6.8% | +18.4% | +6.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 655.02M | 633.32M | 598.58M |
| Total Equity | 792.09M | 852.79M | 739.85M |
| D/E Ratio | 0.83 | 0.74 | 0.81 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |